spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck to Provide Provantage® End-to-End Services to Acticor Biotech SAS

Merck Serono

Leading science and technology company announces that it will provide its Provantage services to Acticor Biotech SAS

  • Accelerates development and manufacture of Acticor's antibody fragment that treats ischemic stroke
Darmstadt, Germany, December 5, 2016 - Merck, a leading science and technology company, today announced that it will provide its Provantage® End-to-End services to Acticor Biotech SAS for accelerated development and manufacturing of Acticor's antibody fragment used for the primary treatment of ischemic stroke.

Merck's Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization.

"Our Provantage® End-to-End solution will provide Acticor with a fast and flexible approach to development and clinical-scale manufacturing," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "We look forward to executing full process development for the antibody fragment, which will help accelerate this important new molecule through the pipeline to patients in need."

The turnkey package includes process development, cGMP clinical manufacturing, quality and regulatory support, training, commercial facilities design, engineering and build-up as well as production equipment supply and process technical transfer activities.

"Stroke is the third leading cause of death in the world and the first cause of disabilities in adults," said Gilles Avenard, CEO, Acticor Biotech. "Motivated by these statistics, we are developing innovative therapeutic strategies for safe and effective emergency treatment of the acute phase of ischemic strokes. Through our collaboration with Merck, we now have access to a comprehensive set of development and manufacturing services that will help us deliver on our mission."

Merck's Provantage® End-to-End solution delivers important benefits and addresses key challenges for biopharmaceutical companies at all life cycle stages in any geography, including established biopharmaceutical companies decentralizing manufacturing that must rapidly and efficiently establish local production capabilities. With an end-to-end approach, Merck can facilitate and accelerate transfer of an entire process to a new location. Early-stage companies with limited manufacturing capabilities, resources and infrastructure benefit from a partner with best-in-class unit operations and the support and expertise to develop processes and production facilities.
phone +44 (0) 20 8818 7200
email http://www.merckserono.co.uk/en/index.html
email Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Bigneat is awarded the Queen’s Award by Lord-Lieutenant of Hampshire

Bigneat Ltd, winner of a Queen’s Award for Enterprise earlier this year, received their Award from Nigel Atkinson Esq, HM Lord-Lieutenant of Hampshire on 16th October at the Bigneat factory in Waterlooville.
More info >>


White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement